Athyrium Capital Management’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Athyrium Capital Management’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,600,444	Closed	-$1.26M	–	4
2023 Q3	$1.26M	Hold	14,600,444	–	–	1.11%	6
2023 Q2	$8.18M	Hold	14,600,444	–	–	5.31%	5
2023 Q1	$16.6M	Hold	14,600,444	–	–	5.96%	4
2022 Q4	$16.4M	Hold	14,600,444	–	–	6.87%	5
2022 Q3	$30.7M	Buy	14,600,444 +6,451,612	+79%	+$12.5M	11.48%	4
2022 Q2	$11.1M	Hold	8,148,832	–	–	4.66%	7
2022 Q1	$13.8M	Hold	8,148,832	–	–	4.9%	6
2021 Q4	$8.8M	Buy	+8,148,832	New	+$13.2M	3.14%	5

Other funds holding RVLP

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Athyrium Capital Management's RVLP Position: Q4 2023 in Review

Athyrium Capital Management sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 14,600,444 shares — an estimated $1.26M sold.

Athyrium Capital Management first reported a position in RVLP in Q4 2021 and held it in 8 quarters. The position peaked at $30.7M in Q3 2022. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

Athyrium Capital Management reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Athyrium Capital Management sold 14,600,444 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $1.26M.
Athyrium Capital Management first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2021 and held it in 8 quarters.
Athyrium Capital Management's RVL Pharmaceuticals plc Ordinary Shares position peaked at $30.7M in Q3 2022.
3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on Athyrium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.